TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02201368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin (SpezialölÒ 107®)
Description: * Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin (SpezialölÒ 107®)
Description: * Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT (Medium-Chain Triglycerides)
Description: * Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT (Medium-Chain Triglycerides)
Description: * Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months
Study: NCT00707148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
Study: NCT04727905

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: energy drink
Description: The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: energy drink
Description: The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
Study: NCT03548324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
Study: NCT03744806

Intervention type: DRUG
Intervention: Bevacizumab Injection
Study: NCT02845908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Study: NCT02820935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Study: NCT01115244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 5%
Description: ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
Study: NCT00765102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
Study: NCT03599817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle promotion program
Description: Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
Study: NCT04886843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack
Description: Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: NMES was applied to the nonaffected side ankle dorsiflexors

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NMES
Description: NMES was applied to the nonaffected side ankle dorsiflexors
Study: NCT00660244

Intervention type: DRUG
Intervention: anastrozole
Description: Oral
Study: NCT00594165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
Study: NCT04749485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
Study: NCT02930772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)
Study: NCT01270568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response
Description: Daily practice of relaxation response, reviewed on a weekly basis

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Recollection
Description: Subjects record daily events on a weekly basis for 8 weeks
Study: NCT01057706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chiropractic
Description: spinal manipulation and mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic
Description: spinal manipulation and mobilization

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: strengthening, stretching, balance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: strengthening, stretching, balance
Study: NCT01780519

Intervention type: DRUG
Group type: OTHER
Intervention: lorazepam
Description: single dose of 1 mg lorazepam

Intervention type: DRUG
Group type: OTHER
Intervention: lorazepam
Description: single dose of 1 mg lorazepam

Intervention type: DRUG
Group type: OTHER
Intervention: lorazepam
Description: single dose of 1 mg lorazepam

Intervention type: DRUG
Group type: OTHER
Intervention: lorazepam
Description: single dose of 1 mg lorazepam

Intervention type: DRUG
Group type: OTHER
Intervention: lorazepam
Description: single dose of 1 mg lorazepam
Study: NCT02360241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Use of the robot to locate the fictional needle
Study: NCT04434339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: A volume of 20 ml for each side of erector spinae plane with 0.25% plain bupivacaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis block
Description: A volume of 20 ml for each side of transversus abdominis plane with 0.25% plain bupivacaine
Study: NCT03550495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychiatry involvement
Description: See arm description.
Study: NCT02845908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin plus Leucovorin plus 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin plus Leucovorin plus 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin plus Leucovorin plus 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally PAC
Study: NCT02913677

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutrition
Description: Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
Study: NCT03745651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.
Study: NCT01437436

Intervention type: PROCEDURE
Intervention: ventilation tube
Description: ventilation tube insertion

Intervention type: PROCEDURE
Intervention: ventilation tube
Description: ventilation tube insertion
Study: NCT03719469

Intervention type: DIETARY_SUPPLEMENT
Intervention: Green tea group
Study: NCT02239731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDX104 (4% Doxycycline)
Description: FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FDX104 (4% Doxycycline)
Description: FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
Study: NCT02462590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L. rhamnosus GG - Probiotic
Description: Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Microcrystalline Cellulose
Description: Microcrystalline Cellulose
Study: NCT03004651

Intervention type: OTHER
Intervention: Power Doppler ultrasound
Description: Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)

Intervention type: OTHER
Intervention: Power Doppler ultrasound
Description: Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
Study: NCT02845908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally PAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX plus PAC(ip)
Description: FOLFOX plus intraperitoneally PAC
Study: NCT03745651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 0.75% or 1.5% cream.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Ruxolitinib matching vehicle cream.
Study: NCT02280603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001C
Description: 1ml by topical application twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% minoxidil
Description: 1ml by topical application twice a day
Study: NCT03797534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dose regime
Description: The initial dose of the experimental group will be calculated by the Bayesian model.
Study: NCT02504632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test
Description: Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
Study: NCT02820935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Study: NCT03004651

Intervention type: OTHER
Intervention: Clinical evaluation
Description: swollen joint count (SJC) as componant of SDAI
Study: NCT04614389

Intervention type: OTHER
Group type: OTHER
Intervention: Contrast-enhanced ultrasound
Description: Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio

Intervention type: OTHER
Group type: OTHER
Intervention: Shear Wave Elastography
Description: Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sequoia System
Description: UltraSound System Cleared by FDA 510 (k) K180067
Study: NCT03836287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 15%
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study: NCT03732287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Anesthesia
Description: Application of cooling anesthesia device prior to intravitreal injection
Study: NCT02271334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A006 DPI
Description: Single dose 110 mcg, 1 inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A006 DPI
Description: Single dose 220 mcg, 1 inhalation
Study: NCT03732287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Anesthesia
Description: Application of cooling anesthesia device prior to intravitreal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Anesthesia
Description: Application of cooling anesthesia device prior to intravitreal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Anesthesia
Description: Application of cooling anesthesia device prior to intravitreal injection
Study: NCT02370654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Study: NCT00658346

Intervention type: DRUG
Intervention: Treatment initiation for HIV-1 group O infected patients
Description: The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
Study: NCT02820935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study: NCT02271334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 1 inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 2 inhalations
Study: NCT03984500

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
Study: NCT03456102

Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.

Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.

Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.

Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
Study: NCT01171144

Intervention type: OTHER
Intervention: Epidemiologic Surveillance System of the Ministry of Health of Panama
Description: Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
Study: NCT02820935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT00123305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
Study: NCT00658346

Intervention type: DRUG
Intervention: Treatment initiation for HIV-1 group M infected patients
Description: The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)
Study: NCT04159688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol Challenge
Study: NCT01171144

Intervention type: OTHER
Intervention: Mortality database of the Contraloria General de la Republica
Description: Reviewing the Mortality database of the Contraloria General de la Republica

Intervention type: OTHER
Intervention: Hospital discharge records
Description: Reviewing the hospital discharge records
Study: NCT03661853

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 60 minute psycho-education on alcohol and drugs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Analysis
Description: Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dealing With Cravings
Description: DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.